Genmab — August 2015
-
-
Ser jeg ikke glad ud Bulder: http://play.borsen.dk/social/55dec566ac79c95260fa268f
-
57.000 på køb.
-
-
Godkendt.
-
-
Svedt så mange handler der var i slutauktionen.
-
USD stiger også pænt. Vi har medvind på cykelstien
-
I denne måned blev der også publiceret resultater for elotuzumab i NEJM. http://www.nejm.org/doi/full/10.1056/NEJMoa1505654
-
Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% con
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind